Fritextsökning
Innehållstyper
-
After the threat of tariffs – Novartis invests 230 billion in the USA
Pharmaceutical giant Novartis plans to invest 23 billion dollarsover the next five years to expand its production in the USA. The goal is for all medicines dest...
-
ZEISS unveils AI-powered Research Data Platform
Collaboration with Boehringer Ingelheim champions the future of personalized eye care.
-
ZEISS introduces the new Smartzoom 100
The future of digital microscopy for efficient optical inspections.
-
New Horizons in Biologics & Bioprocessing incl. Advanced Therapies: Copenhagen (2026)
-
The key to successful collaboration between industry and academia
Why is collaboration between industry and academia necessary in the life sciences sector? What obstacles exist, and what is the key to successful collaboration?
-
New moves around Nykode's management – withdrawal of resignations
Norwegian Nykode Therapeutics is reinstating members of the management team who previously announced their resignations.
-
Xbrane enters licensing agreement with Indian generics giant
Swedish biosimilar developer Xbrane Biopharma and the Indian company Intas Pharmaceuticals have entered into a license and co-development agreement.
-
High-performance Slide Scanner for Fluorescence, Brightfield and Polarization
ZEISS Axioscan 7.
-
Discover Precision: Join ZEISS at the Control Fair in Stuttgart
May 6-9, 2025 in Stuttgart. Hall 9, Booth 9309.
-
CT technology for when the inside matters
ZEISS METROTOM 1 now at #HandsOnMetrology.
-
Orexo får USA-stöd för överdosläkemedel vid blandmissbruk
Uppsalabolaget Orexo har fått 8 miljoner dollar, motsvarande 75 miljoner kronor, av den amerikanska myndigheten Barda för att ta fram ett nasalt räddningsläkeme...
-
Tau-targeted Alzheimer's drug gets Fast Track designation in the USA
Biogen's Alzheimer's candidate BIIB080 has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA).
-
Meet us at Control 2025
Innovations that drive efficiency.
-
Ytterligare läkemedelskandidat mot Alzheimers droppas
Ett litet schweiziskt biotechbolag avbryter en fas II-studien med sin läkemedelskandidat mot Alzheimers sjukdom. Beskedet kommer inte långt efter att Biogen och...
-
FDA’s Top Vaccine Official resigns – Issues sharp criticism of Kennedy
FDA’s Top Vaccine Official is leaving his post while simultaneously criticizing the country’s health secretary for allowing “misinformation and lies” to influen...
-
ZEISS supports the transition of spatial biology to clinical research
Slide scanner ZEISS Axioscan 7 spatial biology provides scalable workflow automation.
-
ZEN core now available for all ZEISS scanning electron microscopes
Introducing intuitive, streamlined SEM control over imaging, analytics, and multi-modal workflows.
-
FDA plans to replace animal testing with AI – “Paradigm shift”
The requirement for animal testing in drug development will be phased out and replaced by AI, according to an announcement by the FDA. The decision has been met...
-
Improving Nano-Structured Surfaces for Implants with Scanning Electron Microscopy
Promimic, a Swedish company specializing in the development and marketing of nano-structured surfaces for implants, heavily relies on scanning electron microscopes.
-
Small robots to deliver pharmaceuticals to the body
Robots that can operate inside the body and a platform that combines ultrasound with AI. These are a couple of the technologies that have qualified for a list t...
-
ZEISS continues to drive digital era forward in ophthalmology
2 million digitally planned cataract cases in the U.S. alone.
-
Success for Genmab's antibody-drug conjugate
The Danish company Genmab has received Japanese approval for its treatment for advanced or recurrent cervical cancer.
-
Efficient use of blood plasma
Blood plasma is an indispensable resource in the production of life-saving medicines. It is in high demand on global markets. To make more efficient use of this...
-
Bioscience – Groundbreaking Research & Diagnostics: Gothenburg (2026)